CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 162 enrolled
Drug / intervention
Ethosuximide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02973542
NCT02973542Phase 2Completed
CompareCT.gov

Evaluation of the Efficacy and Tolerance of Ethosuximide in the Treatment of Abdominal Pain Associated With Irritable Bowel Syndrome

University Hospital, Clermont-Ferrand·interventional·Posted Nov 25, 2016·Updated Apr 21, 2026

In Brief

A Phase 2 clinical trial evaluating Ethosuximide and Placebo for Irritable Bowel Syndrome. Completed, enrolled 162 participants across 1 site.

Detailed Summary

Abdominal pain remains the most deleterious symptom for patients with irritable bowel syndrome (IBS) and is causing a significant alteration of their quality of life. The visceral hypersensitivity seems to be one of the key mechanisms that could explain the abdominal pain in these patients. Current treatments, mainly symptomatic, are of limited effectiveness, especially in terms of relief of abdominal pain. The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome
CountriesFrance
CollaboratorsSFETD (Socièté Française d'Etude et de Traitement de la Douleur)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 25, 2016
Enrollment StartFeb 8, 2018
Primary CompletionMar 7, 2023
Study CompletionMay 7, 2023
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 9.6 years ago

Interventions

Ethosuximidedrug

The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.

Placeboother

The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.